US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

SNGX

Soligenix (SNGX)

Soligenix Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SNGX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/16	21 : 30	PR Newswire (US)	Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma	NASDAQ:SNGX	Soligenix Inc
2024/12/14	07 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/14	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
2024/12/02	21 : 30	PR Newswire (US)	HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment	NASDAQ:SNGX	Soligenix Inc
2024/11/19	21 : 30	PR Newswire (US)	Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma	NASDAQ:SNGX	Soligenix Inc
2024/11/14	21 : 15	PR Newswire (US)	Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease	NASDAQ:SNGX	Soligenix Inc
2024/11/09	06 : 14	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
2024/11/09	06 : 12	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
2024/11/09	06 : 10	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
2024/11/09	06 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNGX	Soligenix Inc
2024/11/08	21 : 30	PR Newswire (US)	Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results	NASDAQ:SNGX	Soligenix Inc
2024/10/24	20 : 30	GlobeNewswire Inc.	Soligenix, Inc. to Present at the 2024 ThinkEquity Conference	NASDAQ:SNGX	Soligenix Inc
2024/10/22	20 : 30	PR Newswire (US)	Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin	NASDAQ:SNGX	Soligenix Inc
2024/10/16	20 : 30	PR Newswire (US)	Soligenix Invited to Present at Upcoming Investor Conferences	NASDAQ:SNGX	Soligenix Inc
2024/10/12	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNGX	Soligenix Inc
2024/10/07	20 : 30	PR Newswire (US)	HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference	NASDAQ:SNGX	Soligenix Inc
2024/10/03	20 : 30	PR Newswire (US)	Soligenix Announces Partnership with Sterling Pharma Solutions	NASDAQ:SNGX	Soligenix Inc
2024/09/16	20 : 30	PR Newswire (US)	Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024	NASDAQ:SNGX	Soligenix Inc
2024/09/03	20 : 30	PR Newswire (US)	Soligenix Receives European Patent for Improved Production of Synthetic Hypericin	NASDAQ:SNGX	Soligenix Inc
2024/08/17	05 : 19	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SNGX	Soligenix Inc
2024/08/17	05 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNGX	Soligenix Inc
2024/08/10	05 : 09	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
2024/08/10	05 : 07	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
2024/08/10	05 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNGX	Soligenix Inc

Showing the most relevant articles for your search:NASDAQ:SNGX

1 2 3 4 5 6 7 8 9 10 次へ >>

American Express

Bank of America

US Dollar vs Sterling

Gold vs US Dollar

Health Care Select Sector

Verizon Communications

BNP Paribas (QX)

Invesco QQQ Trust Series 1

JP Morgan Chase

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約